India’s rupee may weaken further, according to analysts, who are watching the central bank’s willingness to defend a currency buffeted by the harshest US tariffs in Asia https://t.co/27UubOY4GK ...

Core Viewpoint - Toyota Motor is anticipated to experience a decline in operating profit for the second consecutive quarter due to U.S. tariffs and supply-chain risks, despite strong global sales of hybrid vehicles [1] Group 1: Financial Performance - The company is expected to report a decrease in quarterly operating profit, marking the second consecutive decline [1] Group 2: Market Conditions - U.S. tariffs are impacting the company's operations negatively [1] - Supply-chain risks are also contributing to the operational challenges faced by the company [1] Group 3: Product Performance - Despite the challenges, there is robust global demand for hybrid vehicles, which remains a positive aspect for the company [1]

Core Insights - GSK raised its 2025 sales and earnings forecasts due to strong growth in its specialty HIV and cancer medicines, leading to a significant increase in share price [1][2] - Despite a decline in U.S. sales of the shingles vaccine Shingrix, GSK's shares have increased by nearly 4% this year, contributing to a total gain of around 25% [1] Sales Performance - Overall vaccine sales reached £2.68 billion in the quarter ending September 30, surpassing analyst expectations of £2.55 billion [3] - Sales outside the U.S. were a key driver of growth, while U.S. sales of Shingrix fell by 15% [3][4] - GSK's influenza vaccine sales also declined in the U.S. due to increased competition [4] Future Outlook - GSK's CEO transition to Luke Miels is anticipated to bring new strategies to navigate U.S. tariffs and offset revenue declines from expiring patents [2][5] - The company aims for annual revenue exceeding £40 billion ($54 billion) by 2031, with current estimates around £34 billion [5] - GSK expects annual revenue growth of 6% to 7% and core earnings per share growth of 10% to 12%, an increase from previous forecasts of 3% to 5% revenue growth and 6% to 8% earnings growth [5][6] Financial Performance - GSK reported core earnings per share of 55 pence on sales of £8.55 billion for the quarter, exceeding analyst expectations of 47.1 pence on £8.24 billion [6] - Revenue in the U.S. business grew by 7% at constant exchange rates, totaling £4.55 billion [6]

Core Insights - Illinois Tool Works Inc. reported mixed third-quarter fiscal 2025 results, with revenue of $4.06 billion, a 2.3% year-over-year increase, but below the expected $4.08 billion [1] - The company narrowed its full-year 2025 GAAP EPS guidance to $10.40-$10.50, aligning with consensus, and projected full-year sales between $16.057 billion and $16.375 billion [2] - The company achieved an EPS of $2.81, a 6% year-over-year growth excluding divestiture gains, and recorded an operating margin of 27.4% alongside a 15% increase in free cash flow [3] Financial Performance - Revenue increased by 2.3% year-over-year to $4.06 billion, missing analyst expectations [1] - Organic revenue growth was reported at 1% year-over-year for the quarter [1] - Earnings per share (EPS) were $2.81, compared to $3.91 a year ago, exceeding the consensus estimate of $2.71 [1] Guidance and Projections - Full-year 2025 GAAP EPS guidance was tightened to $10.40-$10.50 from a previous range of $10.35-$10.55 [2] - Projected full-year sales for 2025 are between $16.057 billion and $16.375 billion, slightly below the consensus of $16.076 billion [2] Market Reaction - Following the earnings announcement, Illinois Tool Works shares rose by 1.1% to $248.45 [4] - Analysts adjusted their price targets, with a consensus rating of "Hold" and a consensus price target of $253.29 [5] Analyst Ratings - Wells Fargo maintained an Underweight rating and lowered the price target from $250 to $245 [7] - Truist Securities maintained a Hold rating and reduced the price target from $298 to $275 [7] - Barclays also maintained an Underweight rating, raising the price target from $243 to $244 [7]

Europe will get a rigorous economic health-check this week, helping gauge the impact of US tariffs on growth and inflation as policymakers convene to set interest rates https://t.co/F6ACwfy09e ...

President Trump said he's ending "all trade negotiations" with Canada because of recent television ads protesting US tariffs. https://t.co/pYgKNSG98g ...

Thailand’s largest group of manufacturers urged the central bank to curb the baht’s strength to lessen the pain for businesses already being crushed by US tariffs https://t.co/KhXvyLntZz ...

Core Insights - Aston Martin has warned of deepening losses this year due to weaker-than-expected demand in North America and Asia-Pacific, compounded by the impact of US tariffs [1][3] - The company no longer anticipates meeting its previous wholesale guidance for 2025 following disappointing third-quarter performance and revised fourth-quarter expectations [2] Financial Performance - Adjusted EBIT for 2025 is now forecasted to be a loss of £-110 million (-$148 million), below market consensus, due to reduced volumes and pressure on gross margins [4] - Capital expenditure for 2025 is expected to be around £375 million, down from an earlier estimate of £400 million, while SG&A is projected to decline by approximately 10% from 2024's £313 million [4] Sales and Deliveries - Wholesale deliveries in Q3 2025 were approximately 1,430 units, below prior guidance and down from 1,641 units in Q3 2024, attributed to softer demand in North America and APAC [6] - Retail volumes in the quarter were consistent with wholesales, but financial performance was negatively impacted by a less favorable mix due to fewer special deliveries [6] Future Outlook - The company does not expect to generate positive free cash flow in the second half of 2025, although it anticipates sequential improvement in Q4 [5] - Aston Martin expects a material improvement in profitability and free cash flow in 2026, supported by consistent Valhalla deliveries and ongoing cost reduction measures [5] Product Development - The company has continued to roll out new core derivatives, with deliveries of the Vanquish Volante beginning in Q3, and expects to start delivering the Vantage S and DBX S in Q4 [7] - Aston Martin completed the sale of shares in AMR GP during Q3, ending the period with total liquidity of approximately £250 million [8]

Core Viewpoint - A report from the State Bank of India (SBI) suggests a potential 25 basis points (bps) cut in the repo rate due to benign inflation, although most economists anticipate the Monetary Policy Committee will maintain the current rate during the announcement on October 1 [1] Group 1 - The SBI report indicates a favorable inflation environment that could justify a rate cut [1] - Economists are divided on the outlook, considering factors such as GST rationalization, US tariffs, and overall growth stability [1]

Monetary Policy - Bank of Canada cut interest rates [1] - The cut is a response to economic and labor market damage from US tariffs [1] - The bank remained vague about future monetary easing plans [1]